What is Infant Bacterial Therapeutics AB PB Ratio?
Infant Bacterial Therapeutics ABFRA:9IB +0.48%13 PB Ratio is 11.05 as of Jul. 04, 2026, which is 514% above its 10-year median of 1.80. GuruFocus rates FRA:9IB with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,228 Biotechnology companies, Infant Bacterial Therapeutics AB ranks worse than 87.46% on this metric.
FRA:9IB'
s PB Ratio Range Over the Past 10 Years
Min: 0.62 Med: 1.8 Max: 10.71
Current: 10.71
During the past 12 years, Infant Bacterial Therapeutics AB's highest PB Ratio was 10.71. The lowest was 0.62. And the median was 1.80.
FRA:9IB's PB Ratio is ranked worse than 87.46% of 1228
companies
in the Biotechnology industry
Industry Median: 2.97
vs FRA:9IB: 10.71
During the past 12 months, Infant Bacterial Therapeutics AB's average Book Value Per Share Growth Rate was -46.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -35.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -27.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -6.90% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Infant Bacterial Therapeutics AB was 89.60% per year. The lowest was -35.80% per year. And the median was -10.80% per year.
Back to Basics: PB Ratio
Infant Bacterial Therapeutics AB (FRA:9IB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Infant Bacterial Therapeutics AB PB Ratio Related Terms
Infant Bacterial Therapeutics AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infant Bacterial Therapeutics AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Infant Bacterial Therapeutics AB's PB Ratio falls into.
Infant Bacterial Therapeutics AB PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Infant Bacterial Therapeutics AB (FRA:9IB) has a PB Ratio of 11.05 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Infant Bacterial Therapeutics AB and its competitors. This is 514% above median its historical median of 1.80. Over the past decade, Infant Bacterial Therapeutics AB's PB Ratio has ranged from 0.62 to 10.71. According to the industry distribution chart, Infant Bacterial Therapeutics AB ranks #1074 out of 1228 companies in the Biotechnology industry, placing it in the top 87.5%.
Is Infant Bacterial Therapeutics AB's PB Ratio too high?
Infant Bacterial Therapeutics AB's current PB Ratio of 11.05 is 514% above median its 10-year median of 1.80. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 10.71. The Biotechnology industry median PB Ratio is 2.97. Infant Bacterial Therapeutics AB's value of 11.05 is 272.1% above this industry median. Based on the distribution chart, Infant Bacterial Therapeutics AB ranks #1074 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Infant Bacterial Therapeutics AB ranks #1074 out of 1228 companies for PB Ratio. This places Infant Bacterial Therapeutics AB in the lower half of its industry. The industry median PB Ratio is 2.97. Infant Bacterial Therapeutics AB's value of 11.05 is 272.1% above this benchmark. Historically, Infant Bacterial Therapeutics AB's own PB Ratio has ranged from 0.62 to 10.71 over the past decade. While the company's 10-year median is 1.80 vs. the industry median of 2.97, Infant Bacterial Therapeutics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infant Bacterial Therapeutics AB's current PB Ratio of 11.05 is 272.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Infant Bacterial Therapeutics AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infant Bacterial Therapeutics AB's current PB Ratio is 11.05, which is 514% above median its own 10-year median of 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (FRA:9IB) has a current PB Ratio of 11.05. The current PB Ratio is 11.05, which is 514% above median its 10-year median of 1.80 and 272.1% above the Biotechnology industry median of 2.97. Infant Bacterial Therapeutics AB's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (FRA:9IB), the current PB Ratio is 11.05 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Infant Bacterial Therapeutics AB Business Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
13GF Score
Get the complete analysis for FRA:9IB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9IB has been successfully added to your 
